NEPH

Business Context and Reporting Period

Company: Nephros, Inc. (NEPH)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2024
Business Overview: Nephros develops and sells high-performance water filtration solutions for medical (infection control, dialysis) and commercial (hospitality, food service) markets. The company operates as a single segment. In 2023, the company dissolved its subsidiary, Specialty Renal Products (SRP), and retained its intellectual property.

Key Financial Metrics

Cash Flow (Six Months Ended June 30, 2024):
- Net cash used in operating activities: $(1,173) thousand
- Net cash used in investing activities: $(50) thousand
- Net cash used in financing activities: $(4) thousand
- Net decrease in cash: $(1,227) thousand

Material Changes vs. Prior Period

• Revenue Decline: Net revenues decreased 8% ($293k) for the quarter and 6% ($468k) for the six months compared to 2023. Management attributes this to a reduction in large, one-time emergency response orders seen in 2023 due to relaxed waterborne risk response requirements.
• Recurring Sales Growth: Despite the overall decline, programmatic or recurring sales increased by 8% (quarter) and 10% (six months) year-over-year, driven by new sales personnel.
• Margin Improvement: Gross margin percentage improved to 61% for the six months ended June 30, 2024, compared to 58% in the prior year, driven by favorable supplier pricing and reduced shipping costs.
• Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 13% for the quarter and 6% for the six months, primarily due to lower bonus accruals, commissions, and stock-based compensation.
• Operating Loss Narrowing: Operating loss improved by 27% for the quarter and 30% for the six months compared to the prior year periods.

Outlook, Risks, and Management Commentary

Liquidity and Capital Resources: The company reported an accumulated deficit of $144.9 million. While operating cash flow was negative for the first half of 2024 due to inventory buildup and receivables growth, management believes current cash balances ($3.1 million) are sufficient to fund operations for at least the next 12 months. The company is focused on turning cash flow positive through sales growth and expense management.

Strategic Focus: Management is investing in inventory to prepare for higher volumes of key products. The company continues to pursue national accounts in the commercial market, which could potentially surpass infection control revenue over time.

Risks and Contingencies:

• Customer Concentration: Three customers accounted for 33% of revenue in Q2 2024 and 36% in the first half of 2024.
• Supplier Commitments: The company has a minimum annual purchase commitment of approximately $4.5 million (€4.2 million) to its supplier, Medica, for the year 2024.
• Going Concern: The company has sustained operating losses every quarter. If operating results do not meet expectations, the company may need to reduce discretionary expenditures, including headcount and R&D.
• Regulatory and Market Risks: Risks include market acceptance of products, potential product liability, and the ability to secure funding if needed.

Investor Verification Checklist

• Cash Runway: Verify if the $3.1 million cash balance is sufficient given the negative operating cash flow of $1.2 million in the first half of the year.
• Revenue Mix: Assess the sustainability of recurring sales growth versus the volatility of emergency response orders.
• Inventory Levels: Review the $2.8 million inventory balance and the $0.5 million increase in the first half of 2024 to ensure it aligns with demand forecasts.
• Supplier Dependency: Confirm the status of the $4.5 million annual purchase commitment to Medica and the impact of the 2024 royalty elimination.
• Customer Concentration: Monitor the financial health of the top three customers who represent over one-third of revenue.